The Neuroprotective Effect of L-Carnitine against Glyceraldehyde-Induced Metabolic Impairment: Possible Implications in Alzheimer’s Disease

Alzheimer’s disease (AD) is a neurodegenerative disorder characterized by progressive cognitive regression and memory loss. Dysfunctions of both glucose metabolism and mitochondrial dynamics have been recognized as the main upstream events of the degenerative processes leading to AD. It has been rec...

Full description

Bibliographic Details
Main Authors: Simona Magi, Alessandra Preziuso, Silvia Piccirillo, Francesca Giampieri, Danila Cianciosi, Monia Orciani, Salvatore Amoroso
Format: Article
Language:English
Published: MDPI AG 2021-08-01
Series:Cells
Subjects:
Online Access:https://www.mdpi.com/2073-4409/10/8/2109
id doaj-123fc0015911419b8688b7db73698a78
record_format Article
spelling doaj-123fc0015911419b8688b7db73698a782021-08-26T13:37:42ZengMDPI AGCells2073-44092021-08-01102109210910.3390/cells10082109The Neuroprotective Effect of L-Carnitine against Glyceraldehyde-Induced Metabolic Impairment: Possible Implications in Alzheimer’s DiseaseSimona Magi0Alessandra Preziuso1Silvia Piccirillo2Francesca Giampieri3Danila Cianciosi4Monia Orciani5Salvatore Amoroso6Department of Biomedical Sciences and Public Health, School of Medicine, University “Politecnica delle Marche”, Via Tronto 10/A, 60126 Ancona, ItalyDepartment of Biomedical Sciences and Public Health, School of Medicine, University “Politecnica delle Marche”, Via Tronto 10/A, 60126 Ancona, ItalyDepartment of Biomedical Sciences and Public Health, School of Medicine, University “Politecnica delle Marche”, Via Tronto 10/A, 60126 Ancona, ItalyDepartment of Clinical Sciences, School of Medicine, University “Politecnica delle Marche”, Via Tronto 10/A, 60126 Ancona, ItalyDepartment of Clinical Sciences, School of Medicine, University “Politecnica delle Marche”, Via Tronto 10/A, 60126 Ancona, ItalyDepartment of Clinical and Molecular Sciences-Histology, School of Medicine, University “Politecnica delle Marche”, Via Tronto 10/A, 60126 Ancona, ItalyDepartment of Biomedical Sciences and Public Health, School of Medicine, University “Politecnica delle Marche”, Via Tronto 10/A, 60126 Ancona, ItalyAlzheimer’s disease (AD) is a neurodegenerative disorder characterized by progressive cognitive regression and memory loss. Dysfunctions of both glucose metabolism and mitochondrial dynamics have been recognized as the main upstream events of the degenerative processes leading to AD. It has been recently found that correcting cell metabolism by providing alternative substrates can prevent neuronal injury by retaining mitochondrial function and reducing AD marker levels. Here, we induced an AD-like phenotype by using the glycolysis inhibitor glyceraldehyde (GA) and explored whether L-carnitine (4-N-trimethylamino-3-hydroxybutyric acid, LC) could mitigate neuronal damage, both in SH-SY5Y neuroblastoma cells and in rat primary cortical neurons. We have already reported that GA significantly modified AD marker levels; here we demonstrated that GA dramatically compromised cellular bioenergetic status, as revealed by glycolysis and oxygen consumption rate (OCR) evaluation. We found that LC ameliorated cell survival, improved OCR and ATP synthesis, prevented the loss of the mitochondrial membrane potential (Δψ<sub>m</sub>) and reduced the formation of reactive oxygen species (ROS). Of note, the beneficial effect of LC did not rely on the glycolytic pathway rescue. Finally, we noticed that LC significantly reduced the increase in pTau levels induced by GA. Overall, these findings suggest that the use of LC can promote cell survival in the setting of the metabolic impairments commonly observed in AD. Our data suggest that LC may act by maintaining mitochondrial function and by reducing the pTau level.https://www.mdpi.com/2073-4409/10/8/2109Alzheimer’s diseaseL-carnitinemetabolic dysfunctionsmitochondrial membrane potentialneuronal survivaloxygen consumption rate
collection DOAJ
language English
format Article
sources DOAJ
author Simona Magi
Alessandra Preziuso
Silvia Piccirillo
Francesca Giampieri
Danila Cianciosi
Monia Orciani
Salvatore Amoroso
spellingShingle Simona Magi
Alessandra Preziuso
Silvia Piccirillo
Francesca Giampieri
Danila Cianciosi
Monia Orciani
Salvatore Amoroso
The Neuroprotective Effect of L-Carnitine against Glyceraldehyde-Induced Metabolic Impairment: Possible Implications in Alzheimer’s Disease
Cells
Alzheimer’s disease
L-carnitine
metabolic dysfunctions
mitochondrial membrane potential
neuronal survival
oxygen consumption rate
author_facet Simona Magi
Alessandra Preziuso
Silvia Piccirillo
Francesca Giampieri
Danila Cianciosi
Monia Orciani
Salvatore Amoroso
author_sort Simona Magi
title The Neuroprotective Effect of L-Carnitine against Glyceraldehyde-Induced Metabolic Impairment: Possible Implications in Alzheimer’s Disease
title_short The Neuroprotective Effect of L-Carnitine against Glyceraldehyde-Induced Metabolic Impairment: Possible Implications in Alzheimer’s Disease
title_full The Neuroprotective Effect of L-Carnitine against Glyceraldehyde-Induced Metabolic Impairment: Possible Implications in Alzheimer’s Disease
title_fullStr The Neuroprotective Effect of L-Carnitine against Glyceraldehyde-Induced Metabolic Impairment: Possible Implications in Alzheimer’s Disease
title_full_unstemmed The Neuroprotective Effect of L-Carnitine against Glyceraldehyde-Induced Metabolic Impairment: Possible Implications in Alzheimer’s Disease
title_sort neuroprotective effect of l-carnitine against glyceraldehyde-induced metabolic impairment: possible implications in alzheimer’s disease
publisher MDPI AG
series Cells
issn 2073-4409
publishDate 2021-08-01
description Alzheimer’s disease (AD) is a neurodegenerative disorder characterized by progressive cognitive regression and memory loss. Dysfunctions of both glucose metabolism and mitochondrial dynamics have been recognized as the main upstream events of the degenerative processes leading to AD. It has been recently found that correcting cell metabolism by providing alternative substrates can prevent neuronal injury by retaining mitochondrial function and reducing AD marker levels. Here, we induced an AD-like phenotype by using the glycolysis inhibitor glyceraldehyde (GA) and explored whether L-carnitine (4-N-trimethylamino-3-hydroxybutyric acid, LC) could mitigate neuronal damage, both in SH-SY5Y neuroblastoma cells and in rat primary cortical neurons. We have already reported that GA significantly modified AD marker levels; here we demonstrated that GA dramatically compromised cellular bioenergetic status, as revealed by glycolysis and oxygen consumption rate (OCR) evaluation. We found that LC ameliorated cell survival, improved OCR and ATP synthesis, prevented the loss of the mitochondrial membrane potential (Δψ<sub>m</sub>) and reduced the formation of reactive oxygen species (ROS). Of note, the beneficial effect of LC did not rely on the glycolytic pathway rescue. Finally, we noticed that LC significantly reduced the increase in pTau levels induced by GA. Overall, these findings suggest that the use of LC can promote cell survival in the setting of the metabolic impairments commonly observed in AD. Our data suggest that LC may act by maintaining mitochondrial function and by reducing the pTau level.
topic Alzheimer’s disease
L-carnitine
metabolic dysfunctions
mitochondrial membrane potential
neuronal survival
oxygen consumption rate
url https://www.mdpi.com/2073-4409/10/8/2109
work_keys_str_mv AT simonamagi theneuroprotectiveeffectoflcarnitineagainstglyceraldehydeinducedmetabolicimpairmentpossibleimplicationsinalzheimersdisease
AT alessandrapreziuso theneuroprotectiveeffectoflcarnitineagainstglyceraldehydeinducedmetabolicimpairmentpossibleimplicationsinalzheimersdisease
AT silviapiccirillo theneuroprotectiveeffectoflcarnitineagainstglyceraldehydeinducedmetabolicimpairmentpossibleimplicationsinalzheimersdisease
AT francescagiampieri theneuroprotectiveeffectoflcarnitineagainstglyceraldehydeinducedmetabolicimpairmentpossibleimplicationsinalzheimersdisease
AT danilacianciosi theneuroprotectiveeffectoflcarnitineagainstglyceraldehydeinducedmetabolicimpairmentpossibleimplicationsinalzheimersdisease
AT moniaorciani theneuroprotectiveeffectoflcarnitineagainstglyceraldehydeinducedmetabolicimpairmentpossibleimplicationsinalzheimersdisease
AT salvatoreamoroso theneuroprotectiveeffectoflcarnitineagainstglyceraldehydeinducedmetabolicimpairmentpossibleimplicationsinalzheimersdisease
AT simonamagi neuroprotectiveeffectoflcarnitineagainstglyceraldehydeinducedmetabolicimpairmentpossibleimplicationsinalzheimersdisease
AT alessandrapreziuso neuroprotectiveeffectoflcarnitineagainstglyceraldehydeinducedmetabolicimpairmentpossibleimplicationsinalzheimersdisease
AT silviapiccirillo neuroprotectiveeffectoflcarnitineagainstglyceraldehydeinducedmetabolicimpairmentpossibleimplicationsinalzheimersdisease
AT francescagiampieri neuroprotectiveeffectoflcarnitineagainstglyceraldehydeinducedmetabolicimpairmentpossibleimplicationsinalzheimersdisease
AT danilacianciosi neuroprotectiveeffectoflcarnitineagainstglyceraldehydeinducedmetabolicimpairmentpossibleimplicationsinalzheimersdisease
AT moniaorciani neuroprotectiveeffectoflcarnitineagainstglyceraldehydeinducedmetabolicimpairmentpossibleimplicationsinalzheimersdisease
AT salvatoreamoroso neuroprotectiveeffectoflcarnitineagainstglyceraldehydeinducedmetabolicimpairmentpossibleimplicationsinalzheimersdisease
_version_ 1721194212604510208